Abstract

The soluble amyloid protein procurer α (sAPPα) and β (sAPPβ) have been postulated as promising new cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) and multiple other neurodegenerative diseases, but have failed to meet expectations with their often discordant and even contradictory findings to date. The aim of the study was to systematically explore this issue. Cochrane Library, PubMed, and CNKI were systematically searched without language or date restrictions. This network meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and also adhered to the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines. Twenty studies, comprising ten groups, were eligible and included. Overall, 19 eligible studies with 1634 patients contributed to the analysis of CSF sAPPα levels and 16 eligible studies with 1684 patients contributed to the analysis of CSF sAPPβ levels. CSF sAPPβ levels are significantly higher in AD than in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP); higher in Control than in Depression, CBS and PSP; higher in Parkinson’s disease dementia (PDD) than in CBS and PSP; higher in mild cognitive impairment progressed to AD dementia during the follow-up period (pMCI) than in Depression and PSP; higher in stable mild cognitive impairment (sMCI) than in Depression. With regard to CSF sAPPα levels, there were no significant difference among groups. However, surprisingly, the resultant rankings graphically showed that pMCI populations have the highest levels of CSF sAPPα and sAPPβ. Furthermore, it seemed there was a positive correlation between CSF sAPPα and sAPPβ levels. The measurement of CSF sAPPα and sAPPβ levels may provide an alternative method for the diagnosis of early-stage AD, pMCI, which is conducive to preventive therapy.

中文翻译：

---

阿尔茨海默氏病和其他多种神经退行性疾病中CSFsAPPα和sAPPβ的水平：网络荟萃分析

摘要

可溶性淀粉样蛋白前体蛋白α（sAPPα）和β（sAPPβ）被认为是阿尔茨海默氏病（AD）和其他多种神经退行性疾病的有希望的新型脑脊液（CSF）生物标志物，但由于它们经常不协调甚至是均未达到预期迄今为止相互矛盾的发现。该研究的目的是系统地探讨这个问题。系统地搜索了Cochrane图书馆，PubMed和CNKI，没有语言或日期限制。该网络荟萃分析遵循了系统评价和荟萃分析的首选报告项目（PRISMA）指南，并且还遵循了流行病学观察性研究的荟萃分析（MOOSE）指南。包括10个小组的20项研究符合条件并纳入研究。总体，19项合格研究（1634名患者）有助于分析CSFsAPPα水平，16项合格研究（1684名患者）有助于分析CSFsAPPβ水平。AD中的CSFsAPPβ水平显着高于肾上腺皮质综合征（CBS）和进行性核上性麻痹（PSP）。控制方面比抑郁症，CBS和PSP更高；帕金森氏病痴呆症（PDD）高于CBS和PSP；在随访期（pMCI）中，轻度认知障碍发展为AD痴呆症的发生率高于抑郁症和PSP。稳定的轻度认知障碍（sMCI）高于抑郁症。关于脑脊液sAPPα水平，各组之间无显着差异。但是，令人惊讶的是，所得排名以图形方式显示pMCI群体具有最高水平的CSFsAPPα和sAPPβ。此外，似乎脑脊液sAPPα和sAPPβ水平呈正相关。CSFsAPPα和sAPPβ水平的测量可能为诊断早期AD pMCI提供另一种方法，这有助于预防性治疗。